TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01567228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHICA GIS (enhanced electronic medical record)
Description: An electronic medical record enhanced with geographic information systems will assist physicians in directing patients to community resources for increasing physical activity, preventing dental caries or addressing school problems
Study: NCT02370576

Intervention type: OTHER
Intervention: rating scale application
Description: Administration of validated PTSD, MDD and anxiety disorders rating scales immediately after birth and 1 month postpartum.~rating scale application

Intervention type: OTHER
Intervention: rating scale application
Description: Administration of validated PTSD, MDD and anxiety disorders rating scales immediately after birth and 1 month postpartum.~rating scale application
Study: NCT04610697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Cognitive Remediation consists of exercises, preferably supported by coaching, aimed at engaging cognitive skills and, as a result, at improving cognition as well as functional and clinical outcomes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Active control condition for cognitive remediation, matched in terms of session modality, number, duration, frequency, and format.
Study: NCT04294745

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buccal infiltration
Description: Injection of local anaesthetic parallel to the Long axis of the tooth in the depth of buccal sulcus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior alveolar nerve block
Description: Standard technique of mandibular nerve block
Study: NCT00450385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 on day 1 for 6 to 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2 IV on day 1 for 6 to 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m2 on day 1 for 6 to 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 40 mg/m2 orally days 1-5, repeated every 21 days for 6 to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1 for 6 to 8 cycles
Study: NCT04600310

Intervention type: DEVICE
Group type: OTHER
Intervention: ULTRAPREP
Description: ULTRAPREP device for reducing OR prep times.
Study: NCT04296292

Intervention type: OTHER
Intervention: In-depth interviews
Description: In-depth interviews following a narrative line of enquiry and direct observation at each of the research sites

Intervention type: OTHER
Intervention: In-depth interviews
Description: In-depth interviews following a narrative line of enquiry and direct observation at each of the research sites
Study: NCT04600310

Intervention type: DEVICE
Group type: OTHER
Intervention: No Intervention
Description: Conventional skin preparation technique
Study: NCT01286831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]GW642444
Description: Single 200μg dose of \[14C\]GW642444 given on Day 1.
Study: NCT03877081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Administration of oral probiotics with 2 doses a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of oral placebo with 2 doses a day
Study: NCT00400153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrovent Respimat (20 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COMBIVENT MDI (36/206 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combivent Respimat (20 mcg/100 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo via corresponding inhaler for blinding purposes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo via corresponding inhaler for blinding purposes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo via corresponding inhaler for blinding purposes
Study: NCT04473573

Intervention type: DEVICE
Group type: OTHER
Intervention: Spartan Cube CYP2C19 System
Description: Using buccal material, determine the genotype of the \*2, \*3 and \*17 SNPs of the CYP2C19 gene on the Spartan Cube CYP2C19 System.
Study: NCT02933515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga and occupational therapy
Description: group OT addressed fall risk factors, such as risk factors inside and outside and how to best manage them. yoga was delivered in sitting, standing, and floor postures
Study: NCT05542615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolonged-Release Pirfenidone
Description: 1200 mg / day of Pirfenidone (KitosCell® LP)
Study: NCT01147965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AD5 CEA Vaccine
Description: AD5\[E1-, E2b-\]-CEA Vector Vaccine
Study: NCT00658333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated Mycophenolate Acid (EC-MPA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil (MMF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MMF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo EC-MPA
Study: NCT01057264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAI Abraxane
Description: Starting dose: 120 mg/m\^2 by HAI infusion over 24 hours on Day 1 of 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Starting dose: 600 mg/m\^2 by IV on Days 1 and 8 of 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg IV on Day 1 of 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 mcg/kg subcutaneously starting at least 24 hours after Day 1 completion of chemotherapy, for 3 days.
Study: NCT02660554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polymerase Chain Reaction (PCR)
Description: Respiratory samples called bronchoalveolar lavage (BAL) gathered from subjects in the PCR arm will be tested for the presence of MRSA using the Cepheid Xpert® Assay. Xpert® is a qualitative in vitro test designed for rapid detection and differentiation of Staphylococcus aureus (SA) and methicillin resistant Staphylococcus aureus (MRSA) using PCR amplification. MRSA is identified by the mecA gene and staphylococcal cassette chromosome mec (SCCmec). Xpert® Assay is approved by the Federal Drug Administration to detect MRSA in soft tissue samples. Once the PCR is completed, the results will be relayed to the treating physician, and antibiotic therapy (vancomycin or linezolid) will be started or stopped based on the study protocol. All BAL samples will be sent for routine bacterial cultures.
Study: NCT03445676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABHR directly on gloves
Description: HCW will be directed by study personnel to use alcohol-based hand rub (ABHR) to cleanse gloves at each hand hygiene opportunity

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ABHR directly on gloves
Description: HCW will be directed by study personnel to use alcohol-based hand rub (ABHR) to cleanse gloves at each hand hygiene opportunity
Study: NCT03787433

Intervention type: DEVICE
Intervention: ARC - Assisted Rehabilitation Care
Description: ARC is a platform based on wearable inertial sensors and machine learning algorithms, designed to bring the rehabilitation at post-stroke patients' home, following hospital discharge.~The product has been created with the purpose to improve physical skills and patient independence accordingly, in the six months following the acute event. ARC aims to optimize, ease and make more accessible the path of post-stroke rehabilitation during post-acute phase, in real life settings.
Study: NCT02498223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experiment protocol
Description: the subjects will undergo the following experiment protocol:~1. recruitment and medical examination day.~2. physiological evaluation day- the subjects will perform twice\* a physiological stress protocol ; 3 min sitting followed by 20 min walking on treadmill (4 km/h, 4% slope), and then 3 min sitting for recovery examination. total 26 min.~3. biomechanical valuation day- the subjects will perform twice\* a biomechanical protocol using the Zebris system; 2 min standing followed by 10 min walking on treadmill (4 km/h, 4% slope). total 12 min.~   * once carrying the weight calculated according to the army current instructions, and a second time carrying weight calculated according to the new LCI. 2 hours rest between the two performances.
Study: NCT03396549

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: new sham tDCS
Description: 1 ch TCT transcranial stimulator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tDCS
Description: 1 ch TCT transcranial stimulator
Study: NCT03089567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride
Description: 5% Sodium Fluoride Varnish used for dental caries prevention and desensitizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: 38% Silver Diamine Fluoride used for dental caries prevention and desensitizer
Study: NCT01225068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: Total of 100 mg (50 mg twice a day) for 6 weeks. Option to increase to 200 mg (100 mg twice a day) after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 matching pills per day for 6 weeks. Option to increase dose after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
Study: NCT01506791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine and pseudoephedrine
Description: Desloratadine and pseudoephedrine 5/240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine and pseudoephedrine
Description: Desloratadine and pseudoephedrine 5/240 mg
Study: NCT02231203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omegaven
Description: 2 infusions, 2 ml/kg, one the night before operation and one the day after operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 infusions, 2 ml/kg, one the night before operation and one the day after operation
Study: NCT01784471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magic Foot™
Description: Magic Foot™ is a shoe, providing massage together with acupressure or reflexology functions. The device is fully remotely operated and controlled.
Study: NCT02597595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spirulina
Description: oral spirulina (tablet=500mg) will be given to patients for 3 months in a dose of 250 mg/kg/day (maximum 4 gm)
Study: NCT00124540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo resembling misoprosotl
Study: NCT04054713

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Acetic acid chromoendoscopy
Description: Acetic acid is prepared at a concentration of 2.5% in a 20ml syringe, it will be applied with a 7 french spray catheter compatible with a working channel 2.8mm onwards, starting the proximal application When distally performing a uniform application on the area of intestinal metaplasia and the timed time for mucous visualization in search of areas of loss of acetowhitening begins, in case of finding such area will be registered the time in which there was loss of acetowhitening, the distance at which it is located from the upper dental arch in addition to the face on which the area is located, subsequently evaluation of the glandular pattern is performed only by classifying as normal or abnormal, once this evaluation has been carried out, biopsies are directed to these areas to be sent to the pathology service.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Seattle protocol
Description: Take random biopsies by quadrants every 2 centimeters. Biopsy of the intestinal metaplasia areas 1cm above the esophagogastric junction will be initiated, taking tissue every 2cm from the four quadrants, separating the biopsies in different bottles based on the length in which they were taken, to later be sent to the pathology service.
Study: NCT00149214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 600 mg/m2, intravenous (IV), every 21 days, 4 cycles (1-4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 60 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: 60 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 100 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (5-8)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 100 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (5-8)
Study: NCT00539721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant Dose 1
Description: Rolapitant 5 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant Dose 2
Description: Rolapitant 20 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
Study: NCT01030133

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Receiver Role Real TMS
Description: In two of the four visits, the participant will be assigned to the receiver condition receiving Real TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The receiver's performance on the task will be unrelated to his/her stimulus painfulness. Each participant will play each role twice.

Intervention type: DEVICE
Group type: OTHER
Intervention: Operator Role Sham TMS
Description: In two of the four visits, the participant will be assigned to the operator condition receiving Sham TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Operator Role Sham TMS
Description: In two of the four visits, the participant will be assigned to the operator condition receiving Sham TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Receiver Role Sham TMS
Description: In two of the four visits, the participant will be assigned to the receiver condition receiving Sham TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The receiver's performance on the task will be unrelated to his/her stimulus painfulness. Each participant will play each role twice.

Intervention type: DEVICE
Group type: OTHER
Intervention: All Participants Operator Role
Description: All participants in Operator Role (Receiving real or sham TMS)
Study: NCT01837810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 800mg every 8 hours as needed for pain
Study: NCT02182700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol sulfate + ipratropium bromide
Description: 120 mcg (salbutamol sulfate) + 20 mcg (ipratropium bromide), inhalation (metered aerosol plus spacer)
Study: NCT00947388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Bendamustine 70 mg/m2 IV Day 8 and 9 every 28 days for 6 courses of therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Given subcutaneously (SC)on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26.
Study: NCT00673114

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: haplo/cord transplant
Description: T-cell depleted haplo-matched cells from related donor and unrelated umbilical cord blood
Study: NCT02765971

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gums
Description: Group A, 180 women will receive sugarless gum after their operating room discharge by 3 hours for at least half an hour at two hours interval.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: picolax drops
Description: Group B, 180 women will receive laxatives after their operating room discharge by 3 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Group C received 500 cc of normal saline, Intravenous fluid
Study: NCT04473573

Intervention type: DEVICE
Group type: OTHER
Intervention: Spartan Cube CYP2C19 System
Description: Using buccal material, determine the genotype of the \*2, \*3 and \*17 SNPs of the CYP2C19 gene on the Spartan Cube CYP2C19 System.

Intervention type: DEVICE
Group type: OTHER
Intervention: Spartan Cube CYP2C19 System
Description: Using buccal material, determine the genotype of the \*2, \*3 and \*17 SNPs of the CYP2C19 gene on the Spartan Cube CYP2C19 System.
Study: NCT02576769

Intervention type: OTHER
Intervention: No intervention
Study: NCT03368573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QbTest
Description: QbTest is a computerised assessment which takes approximately 20mins. The test combines a continuous performance test alongside an infrared camera which measures the participant's movements. The infrared camera measures motor activity of the participant whilst they undertake the task. During the test, the participant is presented with continuously changing stimuli. Embedded within these stimuli is a given target. Participants have to respond by pressing a hand-held button only when the target appears. Attention is measured through omission errors and reaction time to response. Impulsivity is assessed through commission errors and anticipatory errors. Motor activity is measured through head movements during the task. The test is approved by the FDA (Ref: K133382) and CE marked.
Study: NCT02201511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg PF-06412562 MR tablets_Fasted
Description: A single modified release tablet with 3 mg PF-06412562 administered after an overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 x 15 mg PF-06412562 MR tablets_Fasted
Description: Two 15 mg PF-06412562 modified release tablets administered after an overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 x 15 mg PF-06412562 MR tablets_Fed
Description: Two 15 mg PF-06412562 modified release tablets administered after a high fat breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg PF-06412562 IR tablets
Description: a single immediate release tablet of 10 mg PF-06412562 after an overnight fast
Study: NCT00423696

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study: NCT00539721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant Dose 3
Description: Rolapitant 70 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant Dose 4
Description: 200 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
Study: NCT03534453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib 300mg tablets
Description: 300mg Olaparib tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
Study: NCT02125773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informed Risk Score
Description: Subjects in the intervention arm will receive an estimate of their risk of HIV infection as estimated by the UCSD calculator. The risk of HIV infection will be based on the subject's responses to the self-reported sexual risk questionnaire and the risk of HIV infection in one year will be extrapolated based on continuation of the same risk behavior. The subjects will also be provided the calculated risk if they were to take PrEP. Subjects in the control arm will not be provided with the results of the risk calculators. Both arms will receive standard of care risk reduction education and information sheets about PrEP.
Study: NCT03340428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Community Adherence Club (TCAC)
Description: A behavioral intervention targeting stigma and care challenges through care delivery, social capital through a group setting, improved job prospects through referrals and training, and substance use through referrals. Participants assigned to this group will meet at least every month in a group of 5-15 members for approximately 2 hours. During the meeting there will be facilitated group discussion, an interactive curriculum including life skills, economic skills, HIV and health, and disclosure and stigma. Individual health screening and distribution of prepackaged medications conclude the session. Individual referrals for specific services (e.g. mental health or substance use management) will be available.
Study: NCT03849755

Intervention type: DEVICE
Group type: OTHER
Intervention: PEPPER system
Description: The PEPPER system offers insulin dosing advice that is highly adaptive to the insulin needs of individuals by using Case-Base Reasoning (CBR) approach.

Intervention type: DEVICE
Group type: OTHER
Intervention: PEPPER system
Description: The PEPPER system offers insulin dosing advice that is highly adaptive to the insulin needs of individuals by using Case-Base Reasoning (CBR) approach.